Subretinal neovascular membrane in idiopathic intracranial hypertension.
OBJECTIVE
To define the prevalence, natural history, treatment, and prognosis of papilledema-related juxtapapillary subretinal neovascular membranes (SRNVMs).


METHODS
Retrospective observational case series.


METHODS
We conducted a retrospective chart review.


RESULTS
Of 1140 cases of idiopathic intracranial hypertension, six patients had juxtapapillary SRNVM. Three patients were observed, and their final visual acuities were 20/20, 20/50, and 20/200. Three SRNVM involved the fovea; two of the cases were treated with argon laser therapy, and one case was treated with photodynamic therapy.


CONCLUSIONS
SRNVM in idiopathic intracranial hypertension is rare (0.53%). Most cases of juxtapapillary SRNVM are self-limited and regress, can be observed, and have a favorable visual prognosis. The progression of the SRNVM ophthalmoscopically or angiographically toward the fovea, however, might be an indication for laser treatment. Once subfoveal extension occurs, the visual outcome tends to be unfavorable. No patients had recurrence of SRNVM after the resolution of the papilledema.
Wendel
Lucas
L
Department of Ophthalmology & Visual Science, University of Iowa Hospitals and Clinics, 200 Hawkins Drive PFP, Iowa City, IA 52242, USA.
Lee
Andrew G
AG
Boldt
H Culver
HC
Kardon
Randy H
RH
Wall
Michael
M
D000086:Acetazolamide / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004232:Diuretics / Q000627:therapeutic use; D005260:Female; D005665:Furosemide / Q000627:therapeutic use; D006801:Humans; D017075:Laser Coagulation; D008297:Male; D008875:Middle Aged; D010211:Papilledema / Q000150:complications* / Q000188:drug therapy; D010778:Photochemotherapy; D015995:Prevalence; D011379:Prognosis; D011559:Pseudotumor Cerebri / Q000150:complications* / Q000188:drug therapy; D015861:Retinal Neovascularization / Q000209:etiology* / Q000628:therapy; D012189:Retrospective Studies; D014792:Visual Acuity
D004232:Diuretics; D005665:Furosemide; D000086:Acetazolamide